Virtual healthcare company Teladoc (NYSE:TDOC) delivered mixed Q4 performance. However, its stock fell over 18% in Tuesday’s after-hours trading due to the downbeat Q1 and 2024 outlook.
Teladoc delivered revenue of $660.5 million, up 4% year-over-year. However, its sales fell short of analysts’ average estimate of $670.8 million. Its Integrated Care segment revenue increased 8% year-over-year to $384.4 million in Q4. However, the BetterHelp segment’s revenue fell slightly.
Teladoc reported a net loss of $0.17 per share in Q4, narrower than its loss per share in the prior-year quarter and analysts’ estimate of $0.22. With this backdrop, let’s delve into its Q1 and 2024 guidance.
Teladoc: Q1 and 2024 Sales Outlook Miss Expectations
Teladoc expects Q1 2024 revenue to be in the range of $630 million to $645 million, compared to analysts’ forecast of $673 million.
Moreover, net loss per share is projected to be $0.45 to $0.55, wider than the Street’s loss expectations of $0.41 per share. As for the full year, the company’s top line is expected to be between $2.64 billion and $2.74 billion, lower than the consensus estimate of $2.77 billion. Nonetheless, the full-year loss per share projection is narrower than the analysts’ forecast.
What is the Prediction for Teladoc Stock?
Teladoc stock has lost over 28% of its value in one year. Further, the lower-than-expected Q1 and 2024 revenue outlook could pressure its share price. However, its large installed base of nearly 90 million virtual care members and a focus on lowering expenses keep analysts cautiously optimistic about its prospects.
Teladoc stock has three Buy and six Hold recommendations for a Moderate Buy consensus rating. Analysts’ average price target of $24.38 implies 18.98% upside potential from current levels.
